alexa Endogenous Opioids|Omics Group|Journal Of Neurology And Neurophysiology

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Endogenous Opioids

Multiple sclerosis (MS) is a chronic and debilitating autoimmune disease of the central nervous system (CNS) that affects approximately 400,000 individuals in the United States and 2 million individuals worldwide. MS occurs in two forms – progressive (primary or secondary) and relapse-remitting, and many patients with relapse remitting forms often develop a more progressive, non-remitting disorder later in life. Although the etiology of MS is unknown, women and individuals of countries in northern latitudes have a greater incidence of MS; deficiencies in vitamin D absorption and some genetic instability are traits associated with the disorder. MS is a triphasic disease involving astrocyte activation that leads to inflammation and recruitment of activated T cells to the CNS approved seven treatments that target myelin repair and neuroprotection including β-interferon products marketed as Betaferon, Avonex or Rebif, glatiramer acetate (Copaxone), natalizumba (Tysabri), fingolimod (Gilenya) and mitozantrone (Novantrone). Many of these therapies carry warnings of serious and possibly life-threatening side effects.
 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords